沙格列汀对改善2型糖尿病患者血压的效果及其作用机制

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the blood pressure-lowing effects of saxagliptin in patients with type 2 diabetes, to study the mechanisms of the beneficial effects of saxagliptin on heart and blood vessels. Methods 78 patients with type 2 diabetes mellitus failing in blood glucose control but with stabilized blood pressure or not having their hypotensive drugs changed over the previous three months were randomly divided into study group(43) and control group(35). The study group was treated with saxagliptin while the control group received increased original dose or added with other hypoglycemic agents for three months. Then the levels of fasting and postprandial blood glucose, glycosylated hemoglobin(HbA₁c), body mass index(BMI), and blood pressure were measured after therapy. Results The fasting plasma glucose (FPG), postprandial glucose (PPG) and HbA1c significantly decreased after treatment in the two groups (P<0.05); while the systolic blood pressure (SBP) [ (133.9±16.5) mmHg vs (125.2±13.4) mmHg), P<0.01], 24 h mean systolic blood pressure[ (125.2±11.7) mmHg vs (116.6±8.6) mmHg, P<0.01] decreased significantly in treatment group after treatment, but no significant change in the control group.However, the degree of the decrease in HbA₁c、FPG and PPG levels was not significantly correlated with that of SBP by Spearman rank correlation. Conclusions Saxagliptin decreases not only blood glucose but also systolic pressure in patients with type 2 diabetes mellitus.

Key words： saxagliptin dipeptidyl peptidase-4 inhibitor diabetes mellitus, type 2 hypertension

Received: 05 August 2014

ZTFLH:

R587.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2015/V26/I1/44

[1]	Cook W, Bryzinski B, Slater J, et al. Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trials[J]. Postgrad Med, 2013, 125(3):145-154.
[2]	王文, 林曙光, 朱鼎良, 等. 推广《中国血压测量指南》, 规范化测量血压[J].中华高血压杂志, 2012, 20(3):201-202.
[3]	Aroda V R, Henry R R, Han J, et al. Efficacy of GLP-1 agonists and DPP-4 inhibitors: meta-analysis and systematic review[J]. Clin Ther, 2012, 34(6):1247-1258.
[4]	Ogawa S, Ishiki M, Nako K, et al. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes[J]. Ohoku J Exp Med, 2011, 223(2): 133-135.
[5]	Mistry G C, Maes A L, Lasseter K C, et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension[J]. J Clin Pharmacol, 2008, 48(5): 592-598.
[6]	Pacheco B P, Crajoinas R O, Couto G K, et al. Dipetidyl peptidase Ⅳ attenuates blood pressure rising in young spontaneously hypertensive rats[J]. J hypertens, 2011, 29(3):520-528.
[7]	Shah Z, Pineda C, Kampfrath T, et al. Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways Vascul Pharmacol[J]. Vascul Pharmacol, 2011, 55(13):2-9.
[8]	Mason R P, Jacob R F, Kubant R, et al. Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive rats[J]. J Cardiovasc Pharmacol, 2012, 60(5):467-473.